Table 1 Clinical characteristics of the study participants

From: Plasma metabolomics reveals the shared and distinct metabolic disturbances associated with cardiovascular events in coronary artery disease

Variable

Discovery set

Validation set

Case (n = 167)

Control (n = 167)

Case (n = 166)

Control (n = 166)

Demographics

   Age, years

70.1 [63.9, 77.0]

68.0 [61.5, 74.3]

65.9 [60.3, 73.6]

68.4 [62.2, 74.7]

   Body mass index, kg/m2

24.5 [22.2, 27.2]

24.9 [22.9, 27.0]

25.0 [23.2, 27.4]

24.8 [22.7, 27.1]

   Males, n (%)

107 (64.1)

100 (59.9)

105 (63.3)

99 (59.6)

Risk factors and medical history

   Current smokers, n (%)

34 (20.4)

30 (18.0)

35 (21.1)

32 (19.3)

   Hypertension, n (%)

122 (73.1)

119 (71.3)

117 (70.5)

125 (75.3)

   Diabetes mellitus, n (%)

65 (38.9)

75 (44.9)

77 (46.4)

79 (47.6)

   Congestive heart failure, n (%)

5 (3.0)

1 (0.6)

3 (1.8)

0 (0.0)

   Peripheral arterial disease, n (%)

7 (4.2)

4 (2.4)

3 (1.8)

5 (3.0)

   Previous myocardial infarction, n (%)

32 (19.2)

33 (19.8)

38 (22.9)

29 (17.5)

   Previous stroke, n (%)

31 (18.6)

22 (13.2)

36 (21.7)

27 (16.3)

   Previous PCI/CABG, n (%)

36 (21.6)

39 (23.4)

39 (23.5)

35 (21.1)

   eGFR, mL/min/1.73 m2

90.2 [71.6, 111.3]

100.4 [84.7, 117.0]

93.7 [73.6, 113.5]

99.4 [82.2, 119.9]

   Coronary stenosis (≥50%), n (%)

54 (32.3)

48 (28.7)

52 (31.3)

47 (28.3)

   Echo left ventricular ejection fractions

45.0 [35.0, 60.0]

60.0 [48.8, 66.0]

56.0 [37.5, 62.0]

61.0 [55.0, 65.0]

Pre-hospital medications

   β receptor blockers, n (%)

55 (32.9)

66 (39.5)

66 (40.7)

63 (39.6)

   ACEI/ARB, n (%)

40 (24.2)

43 (26.1)

44 (27.0)

54 (34.2)

   Statins, n (%)

77 (46.1)

84 (50.6)

85 (52.5)

94 (59.9)

   Aspirin, n (%)

111 (67.3)

113 (68.1)

119 (73.0)

123 (76.9)

Admission characteristics

   Heart rate, beats/min

75.0 [63.0, 87.5]

72.0 [63.0, 80.0]

77.0 [67.0, 84.0]

70.0 [64.0, 78.0]

   Systolic blood pressure, mmHg

131.0 [117.5, 146.5]

134.0 [118.0, 149.0]

134.5 [123.0, 153.8]

139.0 [127.0, 153.0]

Admission diagnosis

   Stable angina, n (%)

10 (6.0)

19 (11.4)

7 (4.2)

16 (9.6)

   Acute coronary syndrome, n (%)

157 (94.0)

148 (88.6)

159 (95.8)

150 (90.4)

Biochemical analyses

   Hemoglobin, g/L

129.0 [118.5, 142.0]

135.0 [125.0, 144.0]

130.0 [119.0, 145.0]

133.0 [125.0, 143.0]

   White blood cell, 109/L

6.5 [5.6, 7.6]

6.0 [5.0, 7.2]

6.9 [5.6, 8.4]

6.3 [5.4, 7.3]

   LDL-C, mmol/L

2.3 [1.8, 2.8]

2.2 [1.7, 2.9]

2.4 [1.8, 2.9]

2.1 [1.8, 2.7]

   HDL-C, mmol/L

1.0 [0.8, 1.2]

1.0 [0.9, 1.2]

1.0 [0.8, 1.2]

1.0 [0.9, 1.2]

   Triglycerides, mmol/L

1.3 [1.1, 1.8]

1.3 [0.9, 1.7]

1.4 [1.0, 2.1]

1.4 [1.0, 1.9]

   Creatinine, μmoI/L

77.0 [65.5, 93.5]

71.0 [60.0, 85.0]

75.5 [65.0, 92.8]

70.0 [61.0, 83.0]

   Cystatin C, mg/L

1.0 [0.8, 1.3]

0.9 [0.8, 1.1]

1.0 [0.9, 1.3]

1.0 [0.8, 1.2]

   hs-cTnT, ng/L

51.1 [13.9, 599.9]

11.6 [6.6, 33.2]

36.0 [12.9, 260.8]

14.2 [6.9, 27.7]

   NT-proBNP, ng/L

7.2 [6.0, 8.2]

5.9 [4.8, 6.7]

6.6 [5.5, 7.8]

5.5 [4.5, 6.6]

  1. Case indicates the composite of cardiovascular events. Control indicates no any cardiovascular events. Data are median with interquartile range, or n (%).
  2. ACEI angiotensin converting enzyme inhibitors, ARB angiotensin receptor blocker, CABG coronary artery bypass grafting, eGFR estimated glomerular filtration rate, HDL-C high density lipoprotein-cholesterol, hs-cTnT high-sensitivity cardiac troponin T, LDL-C low density lipoprotein-cholesterol, NT-proBNP N-terminal pro-B-type natriuretic peptide, PCI percutaneous coronary intervention.
Back to article page